Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

IsoRay's Cesium-131 brachytherapy shows positive effect in single-site study; shares ahead 9% premarket

Published 06/20/2017, 08:52 AM
© Reuters.  IsoRay's Cesium-131 brachytherapy shows positive effect in single-site study; shares ahead 9% premarket
CATX
-
  • Thinly traded nano cap IsoRay (NYSEMKT:ISR) perks up 9% premarket on average volume in response to its announcement results from a study performed at NY Presbyterian Hospital assessing low-dose Cesium-131 brachytherapy in brain cancer patients.
  • Results from 42 patients with 46 metastases at least 2 cm in diameter who underwent surgical resection showed no regrowth of their tumors after the intra-operative placement of stranded Cesium-131 seeds into the resection cavity. There were also no cases of radionecrosis observed, a significant unwanted side effect of radiation therapy to the brain.
  • The study was just published in International Journal of Radiation Oncology, Biology, Physics.
  • Now read: Becton Dickinson: Dividend Jewel - In The Service Of Medicine


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.